Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
26/05/2022 15:17
May 26 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - RECEIVED POSITIVE COMMENTS FROM
FDA TO
DETERMINE POTENTIAL NEW CLINICAL ENDPOINTS TO SUPPORT EMERGENCY
USE AUTHORIZATION
* REVIVE THERAPEUTICS LTD - COMPANY WILL SUBMIT A DATA
ACCESS PLAN
TO FDA IN EARLY JUNE 2022 WITH AIM TO UNBLIND PRE-DOSE SELECTION
DATA
* REVIVE THERAPEUTICS - TO SUBMIT DATA ACCESS PLAN TO FDA IN
EARLY
JUNE WITH AIM TO SUBMIT AMENDED STUDY PROTOCOL WITH NEW PRIMARY
EFFICACY ENDPOINTS
Source text for Eikon: ID:nGNXdCGL1
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure